News

Article

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

Author(s):

Fact checked by:

Key Takeaways

  • AI can increase adenoma detection rates by 10-15%, enhancing colonoscopy effectiveness in reducing colorectal cancer risk.
  • Higher adenoma detection rates correlate with lower interval colorectal cancer development, highlighting AI's clinical significance.
SHOW MORE

Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.

Artificial intelligence has proven to be an asset in the enhancement of adenoma detection rates during colonoscopy, according to Dr. Shyam Thakkar, who noted that studies show that artificial intelligence can increase adenoma identification by up to 15%.

In an interview with CURE® on the topic of Colorectal Cancer Awareness Month, Thakkar sat down to discuss the importance of raising awareness for colorectal cancer and how ongoing research initiatives aim to improve patient outcomes, referencing the utility of artificial intelligence in care. Thakker is a professor and director of Advanced Therapeutic Endoscopy in the Department of Medicine, Division of Gastroenterology & Hepatology, at West Virginia University, in Morgantown.

Transcript:

There's a lot of research going on in colorectal cancer right now, especially towards minimizing the impact of colon cancer that's already developed or later stage cancer. [This is done] by understanding tumor biology, the oncologic therapies that are available to help reduce progression and induce remission of disease. Many of the specialty cancer centers have access to these clinical trials. There have been some landmark trials when it comes to screening colonoscopy in and of itself. [Something] that I would like to bring to attention is trials around artificial intelligence, essentially, using what we call Computer Aided Detection to help us identify polyps at the time of colonoscopy

There was a wonderful study that was published in The New England Journal of Medicine that looked at adenoma detection rate. Adenomas are the precursor-type polyps that can develop into cancer. What we know from that study is that endoscopist that had a higher adenoma detection rate, had a lower interval colorectal cancer development in their patient population for those that underwent colonoscopy. What they were able to demonstrate was the higher your adenoma detection rate was, the less chance of a patient developing colorectal cancer in your population. That's one of the reasons why artificial intelligence helps us so much.

What we know from the studies around artificial intelligence is that it can take anyone's adenoma detection rate and give it a bump up. We've seen this bump typically [at] about a 10% to 15% increase in their adenoma detection rate, and the increase in adenomas per colonoscopy that are detected are up to 50% more. The long and short of it is that when it comes to recent research that has been impactful in screening colonoscopy, research and the development around artificial intelligence to help endoscopists find polyps and maximize the application of colonoscopy to minimize the risk of colorectal cancer developing in a patient that's already had a colonoscopy.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content